Previous close | 2.0300 |
Open | 2.0300 |
Bid | 0.8000 |
Ask | 2.9500 |
Strike | 5.00 |
Expiry date | 2024-12-20 |
Day's range | 2.0300 - 2.0300 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: